Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Лечебное дело
2020 / N 2

Клинико-патогенетические особенности кардиомиопатии и сердечной недос
В.Н. Шишкова, А.И. Мартынов

Список литературы

1. Feigin VL, Roth GA, Naghavi M, Parmar P, Krishnamurthi R, Chugh S, Mensah GA, Norrving B, Shiue I, Ng M, Estep K, Cercy K, Murray CJL, Forouzanfar MH; Global Burden of Diseases, Injuries and Risk Factors Study 2013 and Stroke Experts Writing Group. Global burden of stroke and risk factors in 188 countries, during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. The Lancet. Neurology 2016 Aug;15(9):913-24.
2. Bozkurt B, Aguilar D, Deswal A, Dunbar SB, Francis GS, Horwich T, Jessup M, Kosiborod M, Pritchett AM, Ramasubbu K, Rosendorff C, Yancy C; American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; Council on Hypertension; Council on Quality and Outcomes Research. Contributory risk and management of comorbidities of hypertension, obesity, diabetes mellitus, hyperlipidemia, and metabolic syndrome in chronic heart failure: a scientific statement from the American Heart Association. Circulation 2016 Dec;134(23):e535-78.
3. Woodiwiss AJ, Libhaber CD, Majane OH, Libhaber E, Maseko M, Norton GR. Obesity promotes left ventricular concentric rather than eccentric geometric remodeling and hypertrophy independent of blood pressure. American Journal of Hypertension 2008 Oct;21(10):1144-51.
4. Devereux RB, Roman MJ, Paranicas M, O’Grady MJ, Lee ET, Welty TK, Fabsitz RR, Robbins D, Rhoades ER, Howard BV. Impact of diabetes on cardiac structure and function: the strong heart study. Circulation 2000 May;101(19):2271-6.
5. Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. The American Journal of Cardiology 1972 Nov;30(6):595-602.
6. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJV, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WHW, Tsai EJ, Wilkoff BL; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology 2013 Oct;62(16):e147-239.
7. Metra M, Teerlink JR. Heart failure. The Lancet 2017 Oct;390(10106):1981-95.
8. Nakamura M, Sadoshima J. Mechanisms of physiological and pathological cardiac hypertrophy. Nature Reviews. Cardiology 2018 Jul;15(7):387-407.
9. Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS, Stanley WC. Myocardial fatty acid metabolism in health and disease. Physiological Reviews 2010 Jan;90(1):207-58.
10. Harayama T, Riezman H. Understanding the diversity of membrane lipid composition. Nature Reviews. Molecular Cell Biology 2018 May;19(5):281-96.
11. Rijzewijk LJ, van der Meer RW, Smit JWA, Diamant M, Bax JJ, Sammer S, Romijn JA, de Roos A, Lamb HJ. Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. Journal of the American College of Cardiology 2008 Nov;52(22):1793-9.
12. Rijzewijk LJ, van der Meer RW, Lamb HJ, de Jong HWAM, Lubberink M, Romijn JA, Bax JJ, de Roos A, Twisk JW, Heine RJ, Lammertsma AA, Smit JWA, Diamant M. Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with cardiac positron emission tomography and magnetic resonance imaging. Journal of the American College of Cardiology 2009 Oct;54(16):1524-32.
13. Haemmerle G, Moustafa T, Woelkart G, Büttner S, Schmidt A, van de Weijer T, Hesselink M, Jaeger D, Kienesberger PC, Zierler K, Schreiber R, Eichmann T, Kolb D, Kotzbeck P, Schweiger M, Kumari M, Eder S, Schoiswohl G, Wongsiriroj N, Pollak NM, Radner FPW, Preiss-Landl K, Kolbe T, Rülicke T, Pieske B, Trauner M, Lass A, Zimmermann R, Hoefler G, Cinti S, Kershaw EE, Schrauwen P, Madeo F, Mayer B, Zechner R. ATGL-mediated fat catabolism regulates cardiac mitochondrial function via PPAR-α and PGC-1. Nature Medicine 2011 Aug;17(9):1076-85.
14. Bikman BT, Summers SA. Ceramides as modulators of cellular and whole-body metabolism. The Journal of Clinical Investigation 2011 Nov;121(11):4222-30.
15. Jornayvaz FR, Shulman GI. Diacylglycerol activation of protein kinase Cε and hepatic insulin resistance. Cell Metabolism 2012 May;15(5):574-84.
16. McCoin CS, Knotss TA, Adams SH. Acylcarnitines – old actors auditioning for new roles in metabolic physiology. Nature Reviews. Endocrinology 2015 Oct;11(10):617-25.
17. Schooneman MG, Vaz FM, Houten SM, Soeters MR. Acylcarnitines: reflecting or inflicting insulin resistance? Diabetes 2013 Jan;62(1):1-8.
18. Makrecka M, Kuka J, Volska K, Antone U, Sevostjanovs E, Cirule H, Grinberga S, Pugovics O, Dambrova M, Liepinsh E. Long-chain acylcarnitine content determines the pattern of energy metabolism in cardiac mitochondria. Molecular and Cellular Biochemistry 2014 Oct;395(1-2):1-10.
19. Ahmad T, Kelly JP, McGarrah RW, Hellkamp AS, Fiuzat M, Testani JM, Wang TS, Verma A, Samsky MD, Donahue MP, Ilkayeva OR, Bowles DE, Patel CB, Milano CA, Rogers JG, Felker GM, O’Connor CM, Shah SH, Kraus WE. Prognostic implications of long-chain acylcarnitines in heart failure and reversibility with mechanical circulatory support. Journal of the American College of Cardiology 2016 Jan;67(3):291-9.
20. Tsujimoto T, Kajio H. Abdominal obesity is associated with an increased risk of all-cause mortality in patients with HFpEF. Journal of the American College of Cardiology 2017 Dec;70(22):2739-49.
21. Bray GA, Frunbeck G, Ryan DH, Wilding JPH. Management of obesity. The Lancet 2016 May;387(10031):1947-56.
22. Udell JA, Cavender MA, Bhatt DL, Chatterjee S, Farkouh ME, Scirica BM. Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. The Lancet. Diabetology & Endocrinology 2015 May;3(5):356-66.
23. Levelt E, Mahmod M, Piechnik SK, Ariga R, Francis JM, Rodgers CT, Clarke WT, Sabharwal N, Schneider, Karamitsos TD, Clarke K, Rider OJ, Neubauer S. Relationship between left ventricular structural and metabolic remodelling in type 2 diabetes. Diabetes 2016 Jan;65(1):44-52.
24. Levelt E, Gulsin G, Neubauer S, McCann GP. Mechanisms in endocrinology: diabetic cardiomyopathy: pathophysiology and potential metabolic interventions state of the art review. European Journal of Endocrinology 2018 Apr;178(4):R127-39.
25. Abozguia K, Elliot P, McKenna W, Phan TT, Nallur-Shivu G, Ahmed I, Maher AR, Kaur K, Taylor J, Henning A, Ashrafian H, Watkins H, Frenneaux M. Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Circulation 2010 Oct;122(16):1562-9.
26. Распоряжение Правительства РФ от 10 декабря 2018 N 2738-р “Об утверждении перечня жизненно необходимых и важнейших лекарственных препаратов для медицинского применения на 2019 год”.
27. Jaudzems K, Kuka J, Gutsaits A, Zinovjevs K, Kalvinsh I, Liepinsh E, Liepinsh E, Dambrova M. Inhibition of carnitine acetyltransferase by mildronate, a regulator of energy metabolism. Journal of Enzyme Inhibition and Medicinal Chemistry 2009 Dec;24(6):1269-75.
28. Skarda I, Klincare D, Dzerve V, Vitols A, Kukulis I, Kalnins U, Karpov R, Koshelskaya O, Semyonova S, Matveja L, Kalvins I. Modulation of myocardial energy metabolism with mildronate – an effective approach in the treatment of chronic heart failure. Proceedings of the Latvian Academy of Sciences. Section B: Natural, Exact, and Applied Sciences 2001;55(2-3):73-9.
29. Visokinskas A, Kalvins I, Knasiene J, Lesauskaite V, Macijauskiene J, Jankauskiene L. Use of mildronate in geriatric patients with congestive heart failure. Journal of the Indian Academy of Geriatrics 2005 Jan;1(3):110-3.
30. Галявич А.С., Галеева З.М., Балеева Л.В. Эффективность и переносимость милдроната при лечении пациентов с хронической сердечной недостаточностью. Российский кардиологический журнал 2005;10(5):55-9.
31. Митрохин В.Е. Миокардиальная цитопротекция у больных стенокардией и хронической сердечной недостаточностью. Фарматека 2003;12(75):109-11.
32. Семенкова Г.Г., Кокорева Л.В. Сравнительная эффективность лечения больных хронической сердечной недостаточностью с применением миокардиальных цитопротекторов. Российский кардиологический журнал 2007;12(2):77-82.
33. Шишкова В.Н. Коморбидность и полипрогмазия: фокус на цитопротекцию. Consilium Medicum 2016;18(12):73-9.
34. Карпов Р.С., Кошельская О.А., Врублевский А.В., Соколов А.А., Тепляков А.Т., Скарда И., Дзерве В., Клинцаре Д., Витольс А., Калниньш У., Калвиньш И., Матвея Л., Урбане Д. Клиническая эффективность и безопасность милдроната при лечении хронической сердечной недостаточности у больных ишемической болезнью сердца. Кардиология 2000;40(6):69-74.
35. Недошивин А.О., Петрова Н.Н., Кутузова А.Е., Перепеч Н.Б. Качество жизни больных с хронической сердечной недостаточностью. Эффект лечения милдронатом. Терапевтический архив 1999;71(8):10-2.
36. Стаценко М.Е., Туркина С.В., Беленкова С.В., Полетаева Л.В., Дудченко Г.П. Влияние милдроната в составе комбинированной терапии хронической сердечной недостаточности у больных сахарным диабетом типа 2 на углеводный, липидный обмен и показатели оксидативного стресса. Российский кардиологический журнал 2010;2(82):45-51.
37. Dzērve V, Matisone D, Pozdnyakov Y, Oganov R. Mildronate improves the exercise tolerance in patients with stable angina: results of a long term clinical trial. Seminars in Cardiovascular Medicine 2010;16:8.
38. Liepinsh E, Vilskersts R, Zvejniece L, Svalbe B, Skapare E, Kuka J, Cirule H, Grinberga S, Kalvinsh I, Dambrova M. Protective effects of mildronate in an experimental model of type 2 diabetes in Goto-Kakizaki rats. British Journal of Pharmacology 2009 Aug;157(8):1549-56.
39. Dambrova M, Makrecka-Kuka M, Vilskersts R, Makarova E, Kuka J, Liepinsh E. Pharmacological effects of meldonium: biochemical mechanisms and biomarkers of cardiometabolic activity. Pharmacological Research 2016 Nov;113(Pt B):771-80.

References

1. Feigin VL, Roth GA, Naghavi M, Parmar P, Krishnamurthi R, Chugh S, Mensah GA, Norrving B, Shiue I, Ng M, Estep K, Cercy K, Murray CJL, Forouzanfar MH; Global Burden of Diseases, Injuries and Risk Factors Study 2013 and Stroke Experts Writing Group. Global burden of stroke and risk factors in 188 countries, during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. The Lancet. Neurology 2016 Aug;15(9):913-24.
2. Bozkurt B, Aguilar D, Deswal A, Dunbar SB, Francis GS, Horwich T, Jessup M, Kosiborod M, Pritchett AM, Ramasubbu K, Rosendorff C, Yancy C; American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; Council on Hypertension; Council on Quality and Outcomes Research. Contributory risk and management of comorbidities of hypertension, obesity, diabetes mellitus, hyperlipidemia, and metabolic syndrome in chronic heart failure: a scientific statement from the American Heart Association. Circulation 2016 Dec;134(23):e535-78.
3. Woodiwiss AJ, Libhaber CD, Majane OH, Libhaber E, Maseko M, Norton GR. Obesity promotes left ventricular concentric rather than eccentric geometric remodeling and hypertrophy independent of blood pressure. American Journal of Hypertension 2008 Oct;21(10):1144-51.
4. Devereux RB, Roman MJ, Paranicas M, O’Grady MJ, Lee ET, Welty TK, Fabsitz RR, Robbins D, Rhoades ER, Howard BV. Impact of diabetes on cardiac structure and function: the strong heart study. Circulation 2000 May;101(19):2271-6.
5. Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. The American Journal of Cardiology 1972 Nov;30(6):595-602.
6. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJV, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WHW, Tsai EJ, Wilkoff BL; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology 2013 Oct;62(16):e147-239.
7. Metra M, Teerlink JR. Heart failure. The Lancet 2017 Oct;390(10106):1981-95.
8. Nakamura M, Sadoshima J. Mechanisms of physiological and pathological cardiac hypertrophy. Nature Reviews. Cardiology 2018 Jul;15(7):387-407.
9. Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS, Stanley WC. Myocardial fatty acid metabolism in health and disease. Physiological Reviews 2010 Jan;90(1):207-58.
10. Harayama T, Riezman H. Understanding the diversity of membrane lipid composition. Nature Reviews. Molecular Cell Biology 2018 May;19(5):281-96.
11. Rijzewijk LJ, van der Meer RW, Smit JWA, Diamant M, Bax JJ, Sammer S, Romijn JA, de Roos A, Lamb HJ. Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. Journal of the American College of Cardiology 2008 Nov;52(22):1793-9.
12. Rijzewijk LJ, van der Meer RW, Lamb HJ, de Jong HWAM, Lubberink M, Romijn JA, Bax JJ, de Roos A, Twisk JW, Heine RJ, Lammertsma AA, Smit JWA, Diamant M. Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with cardiac positron emission tomography and magnetic resonance imaging. Journal of the American College of Cardiology 2009 Oct;54(16):1524-32.
13. Haemmerle G, Moustafa T, Woelkart G, Büttner S, Schmidt A, van de Weijer T, Hesselink M, Jaeger D, Kienesberger PC, Zierler K, Schreiber R, Eichmann T, Kolb D, Kotzbeck P, Schweiger M, Kumari M, Eder S, Schoiswohl G, Wongsiriroj N, Pollak NM, Radner FPW, Preiss-Landl K, Kolbe T, Rülicke T, Pieske B, Trauner M, Lass A, Zimmermann R, Hoefler G, Cinti S, Kershaw EE, Schrauwen P, Madeo F, Mayer B, Zechner R. ATGL-mediated fat catabolism regulates cardiac mitochondrial function via PPAR-α and PGC-1. Nature Medicine 2011 Aug;17(9):1076-85.
14. Bikman BT, Summers SA. Ceramides as modulators of cellular and whole-body metabolism. The Journal of Clinical Investigation 2011 Nov;121(11):4222-30.
15. Jornayvaz FR, Shulman GI. Diacylglycerol activation of protein kinase Cε and hepatic insulin resistance. Cell Metabolism 2012 May;15(5):574-84.
16. McCoin CS, Knotss TA, Adams SH. Acylcarnitines – old actors auditioning for new roles in metabolic physiology. Nature Reviews. Endocrinology 2015 Oct;11(10):617-25.
17. Schooneman MG, Vaz FM, Houten SM, Soeters MR. Acylcarnitines: reflecting or inflicting insulin resistance? Diabetes 2013 Jan;62(1):1-8.
18. Makrecka M, Kuka J, Volska K, Antone U, Sevostjanovs E, Cirule H, Grinberga S, Pugovics O, Dambrova M, Liepinsh E. Long-chain acylcarnitine content determines the pattern of energy metabolism in cardiac mitochondria. Molecular and Cellular Biochemistry 2014 Oct;395(1-2):1-10.
19. Ahmad T, Kelly JP, McGarrah RW, Hellkamp AS, Fiuzat M, Testani JM, Wang TS, Verma A, Samsky MD, Donahue MP, Ilkayeva OR, Bowles DE, Patel CB, Milano CA, Rogers JG, Felker GM, O’Connor CM, Shah SH, Kraus WE. Prognostic implications of long-chain acylcarnitines in heart failure and reversibility with mechanical circulatory support. Journal of the American College of Cardiology 2016 Jan;67(3):291-9.
20. Tsujimoto T, Kajio H. Abdominal obesity is associated with an increased risk of all-cause mortality in patients with HFpEF. Journal of the American College of Cardiology 2017 Dec;70(22):2739-49.
21. Bray GA, Frunbeck G, Ryan DH, Wilding JPH. Management of obesity. The Lancet 2016 May;387(10031):1947-56.
22. Udell JA, Cavender MA, Bhatt DL, Chatterjee S, Farkouh ME, Scirica BM. Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. The Lancet. Diabetology & Endocrinology 2015 May;3(5):356-66.
23. Levelt E, Mahmod M, Piechnik SK, Ariga R, Francis JM, Rodgers CT, Clarke WT, Sabharwal N, Schneider, Karamitsos TD, Clarke K, Rider OJ, Neubauer S. Relationship between left ventricular structural and metabolic remodelling in type 2 diabetes. Diabetes 2016 Jan;65(1):44-52.
24. Levelt E, Gulsin G, Neubauer S, McCann GP. Mechanisms in endocrinology: diabetic cardiomyopathy: pathophysiology and potential metabolic interventions state of the art review. European Journal of Endocrinology 2018 Apr;178(4):R127-39.
25. Abozguia K, Elliot P, McKenna W, Phan TT, Nallur-Shivu G, Ahmed I, Maher AR, Kaur K, Taylor J, Henning A, Ashrafian H, Watkins H, Frenneaux M. Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Circulation 2010 Oct;122(16):1562-9.
26. Order of the Government of the Russian Federation of December 10, 2018 N 2738-p “On approval of the list of vital and essential medicines for medical use for 2019”. (In Russian).
27. Jaudzems K, Kuka J, Gutsaits A, Zinovjevs K, Kalvinsh I, Liepinsh E, Liepinsh E, Dambrova M. Inhibition of carnitine acetyltransferase by mildronate, a regulator of energy metabolism. Journal of Enzyme Inhibition and Medicinal Chemistry 2009 Dec;24(6):1269-75.
28. Skarda I, Klincare D, Dzerve V, Vitols A, Kukulis I, Kalnins U, Karpov R, Koshelskaya O, Semyonova S, Matveja L, Kalvins I. Modulation of myocardial energy metabolism with mildronate – an effective approach in the treatment of chronic heart failure. Proceedings of the Latvian Academy of Sciences. Section B: Natural, Exact, and Applied Sciences 2001;55(2-3):73-9.
29. Visokinskas A, Kalvins I, Knasiene J, Lesauskaite V, Macijauskiene J, Jankauskiene L. Use of mildronate in geriatric patients with congestive heart failure. Journal of the Indian Academy of Geriatrics 2005 Jan;1(3):110-3.
30. Galyavich AS, Galeyeva ZM, Baleyeva LV. Mildronate efficacy and tolerability in treatment of chronic heart failure patients. Russian Journal of Cardiology 2005;10(5):55-9 (In Russian).
31. Mitrokhin VE. Myocardial cytoprotection in patients with angina and chronic heart failure. Farmateka 2003;12(75):109-11 (In Russian).
32. Semenkova GG, Kokoreva LV. Comparative efficacy of myocardial cytoprotectors in chronic heart failure treatment. Russian Journal of Cardiology 2007;12(2):77-82 (In Russian).
33. Shishkova VN. Comorbidity and polyprogmasia: focus on cytoprotection. Consilium Medicum 2016;18(12):73-9 (In Russian).
34. Karpov RS, Koshelskaya OA, Vrublevskiy AV, Sokolov AA, Teplyakov AT, Skarda I, Dzerve V, Klintsare D, Vitols A, Kalninsh U, Kalvinsh I, Matveya L, Urbane D. Clinical efficacy and safety of mildronate in patients with coronary heart disease. Kardiologiia 2000;40(6):69-74 (In Russian).
35. Nedoshivin AO, Petrova NN, Kutuzova AE, Perepech NB. Life quality of patients with chronic heart failure. Effect of mildronate treatment. Therapeutic Archive 1999;71(8):10-2 (In Russian).
36. Statsenko ME, Turkina SV, Belenkova SV, Poletaeyva LV, Dudchenko GP. Effect of mildronate in combined therapy of chronic heart failure in patients with type 2 diabetes mellitus on carbohydrate, lipid metabolism and oxidative stress indicators. Russian Journal of Cardiology 2010;2(82):45-51 (In Russian).
37. Dzērve V, Matisone D, Pozdnyakov Y, Oganov R. Mildronate improves the exercise tolerance in patients with stable angina: results of a long term clinical trial. Seminars in Cardiovascular Medicine 2010;16:8.
38. Liepinsh E, Vilskersts R, Zvejniece L, Svalbe B, Skapare E, Kuka J, Cirule H, Grinberga S, Kalvinsh I, Dambrova M. Protective effects of mildronate in an experimental model of type 2 diabetes in Goto-Kakizaki rats. British Journal of Pharmacology 2009 Aug;157(8):1549-56.
39. Dambrova M, Makrecka-Kuka M, Vilskersts R, Makarova E, Kuka J, Liepinsh E. Pharmacological effects of meldonium: biochemical mechanisms and biomarkers of cardiometabolic activity. Pharmacological Research 2016 Nov;113(Pt B):771-80.
  

[ Содержание выпуска N 2 | Выпуски журнала | Список журналов ]